Sugammadex versus neostigmine for neuromuscular blockade reversal in outpatient surgeries: A randomized controlled trial to evaluate efficacy and associated healthcare cost in an academic center.
Frontiers in medicine（2022）
摘要
[https://clinicaltrials.gov/] identifier number [NCT03579589].
更多查看译文
关键词
cost-benefit analysis,neostigmine,neuromuscular blockade,neuromuscular blocking agents,rocuronium,sugammadex
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要